Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005785802
Wed, 23.02.2022
Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has filed the annual report 2021 on form 20-F with the U.S. Securities and Exchange Commission (SEC). The report is available at the company's website (freseniusmedicalcare.com) in the "Investors" section as well as at the SEC's websit [ … ]
Tue, 22.02.2022
Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, commits to become climate neutral by 2040. This applies both to direct and indirect CO2 emissions (Scope 1 and 2) - also in view of the expected future business growth. The company is also continuously assessing its emissions across th [ … ]
Tue, 22.02.2022
Fresenius Medical Care AG & Co. KGaA
- Business development significantly impacted by COVID-19 in 2021, effects are expected to continue into 2022
- Decline in excess mortality in the fourth quarter
- 25th consecutive dividend increase to 1.35 EUR proposed
- Implementation of strategic priorities on track
Rice Powell, Chief Executive Officer of Fresenius Medical Care, said: "Througho [ … ]
Wed, 01.12.2021
Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced changes to the Management Board effective on January 1, 2022. They follow a unanimous decision by the Supervisory Board of Fresenius Medical Care Management AG to adapt the composition of the Management Board to the com [ … ]
Tue, 02.11.2021
Fresenius Medical Care AG & Co. KGaA
Stronger than projected headwind from COVID-19 effects with significantly increased patient excess mortality due to global spread of Delta variant
Organic growth continued with 1%
Financial targets for FY 2021 confirmed, expectation to reach lower end of the guidance ranges for revenue and net income
FME25 transformation update to achieve EUR [ … ]
Tue, 02.11.2021
Fresenius Medical Care AG & Co. KGaA
Globalization of operating model to leverage expertise, capture growth opportunities and accelerate value creation
Business operations to be structured in two global operating segments: Care Enablement and Care Delivery
Reduction of annual cost base of EUR 500 million by 2025 with anticipated one-time investments of around EUR 450-500 million
Fi [ … ]
Fri, 30.07.2021
Fresenius Medical Care AG & Co. KGaA
As assumed, COVID-19 pandemic continued to impact organic growth in dialysis and downstream businesses
Patient excess mortality rates significantly reduced
Negative exchange rate effects continue
Earnings development impacted by phasing and strong prior-year base, as indicated
Financial targets for FY 2021 confirmed
FME25 program on track
Rice [ … ]
Thu, 06.05.2021
Fresenius Medical Care AG & Co. KGaA
May 6, 2021
Fresenius Medical Care delivers solid first quarter in light of the COVID-19 pandemic, confirms outlook for 2021
- Organic treatment growth impacted by COVID-19 pandemic as expected
- Reported revenue and earnings continued to be adversely affected by exchange rate effects
- Earnings development supported by phasing and expected low [ … ]
Thu, 06.05.2021
Fresenius Medical Care AG & Co. KGaA
- Organic treatment growth impacted by COVID-19 pandemic as expected
- Reported revenue and earnings continued to be adversely affected by exchange rate effects
- Earnings development supported by phasing and expected lower SG&A expense anticipated to reverse throughout the year
- Vaccination of patients accelerated to 51 percent globally
- Fin [ … ]
Thu, 29.10.2020
Fresenius Medical Care AG & Co. KGaA
- Operations maintained despite COVID-19, impact on patients minimized
- Q3 development impacted by currency headwinds and expected lower reimbursement for calcimimetics
- Financial targets for FY 2020 confirmed inclusive of anticipated COVID-19 effects
"The global COVID-19 pandemic has posed further challenges to us in the third quarter; and it [ … ]